<DOC>
	<DOCNO>NCT00581776</DOCNO>
	<brief_summary>Patients receive Rituximab , Bortezomib , cyclophosphamide , Doxorubicin , Vincristine , Dexamethasone three week interval 6 cycle ; rituximab consolidation ( weekly x 4 ) , one dose rituximab every 12 week 5 year disease progression .</brief_summary>
	<brief_title>Phase II Study VcR-CVAD With Rituximab Consolidation Maintenance Untreated Mantle Cell Lymphoma</brief_title>
	<detailed_description>Primary objective estimate overall response rate ( ORR ) complete response rate ( CRR ) VcR CVAD regimen ( response rate completion induction ) . Patients receive Rituximab , Bortezomib , cyclophosphamide , Doxorubicin , Vincristine , Dexamethasone three week interval 6 cycle ; rituximab consolidation ( weekly x 4 ) , one dose rituximab every 12 week 5 year disease progression .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Histologically confirm CD20+ mantle cell lymphoma , measurable evaluable disease , prior chemotherapy , immunotherapy radiotherapy except 1 cycle CHOPlike chemotherapy . Patients know CNS disease , know HIV infection , grade 2 great peripheral neuropathy , history myocardial infarction last 6 month , patient Hepatitis B Surface Antigen positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Untreated Mantle Cell Lymphoma</keyword>
</DOC>